Stuart J Connolly, MD
November 4th, 2013
Should Plasma Levels of Dabigatran Guide How We Dose the Drug?
Stuart J Connolly, MD
Stuart J. Connolly discusses his research group’s analysis of data from the RE-LY trial, concerning the relationship between plasma concentrations of dabigatran and the risks for ischemic events and major bleeding.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?